Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study

Author:

Kalisvaart Gijsbert1ORCID,Evenhuis Richard2ORCID,Grootjans Willem1,Van Den Berghe Thomas3ORCID,Callens Martijn3ORCID,Bovée Judith4ORCID,Creytens David5ORCID,Gelderblom Hans6ORCID,Speetjens Frank6ORCID,Lapeire Lore7,Sys Gwen8ORCID,Fiocco Marta91011ORCID,Verstraete Koenraad3,van de Sande Michiel210ORCID,Bloem Johan1ORCID

Affiliation:

1. Department of Radiology, Leiden University Medical Center, 2333 Leiden, The Netherlands

2. Department of Orthopedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 Leiden, The Netherlands

3. Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium

4. Department of Pathology, Leiden University Medical Center, 2333 Leiden, The Netherlands

5. Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium

6. Department of Medical Oncology, Leiden University Medical Center, 2333 Leiden, The Netherlands

7. Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium

8. Department of Orthopedic Surgery and Traumatology, Ghent University Hospital, 9000 Ghent, Belgium

9. Department of Biomedical Science, Section Medical Statistics, Leiden University Medical Center, 2333 Leiden, The Netherlands

10. Center for Pediatric Oncology, Princess Maxima Center, 3584 Utrecht, The Netherlands

11. Mathematical Institute, Leiden University, 2300 Leiden, The Netherlands

Abstract

Background: The decreased perfusion of osteosarcoma in dynamic contrast-enhanced (DCE) MRI, reflecting a good histological response to neoadjuvant chemotherapy, has been described. Purpose: In this study, we aim to explore the potential of the relative wash-in rate as a prognostic factor for event-free survival (EFS). Methods: Skeletal high-grade osteosarcoma patients, treated in two tertiary referral centers between 2005 and 2022, were retrospectively included. The relative wash-in rate (rWIR) was determined with DCE-MRI before, after, or during the second cycle of chemotherapy (pre-resection). A previously determined cut-off was used to categorize patients, where rWIR < 2.3 was considered poor and rWIR ≥ 2.3 a good radiological response. EFS was defined as the time from resection to the first event: local recurrence, new metastases, or tumor-related death. EFS was estimated using Kaplan–Meier’s methodology. Multivariate Cox proportional hazard model was used to estimate the effect of histological response and rWIR on EFS, adjusted for traditional prognostic factors. Results: Eighty-two patients (median age: 17 years; IQR: 14–28) were included. The median follow-up duration was 11.8 years (95% CI: 11.0–12.7). During follow-up, 33 events occurred. Poor histological response was not significantly associated with EFS (HR: 1.8; 95% CI: 0.9–3.8), whereas a poor radiological response was associated with a worse EFS (HR: 2.4; 95% CI: 1.1–5.0). In a subpopulation without initial metastases, the binary assessment of rWIR approached statistical significance (HR: 2.3; 95% CI: 1.0–5.2), whereas its continuous evaluation demonstrated a significant association between higher rWIR and improved EFS (HR: 0.7; 95% CI: 0.5–0.9), underlining the effect of response to chemotherapy. The 2- and 5-year EFS for patients with a rWIR ≥ 2.3 were 85% and 75% versus 55% and 50% for patients with a rWIR < 2.3. Conclusion: The predicted poor chemo response with MRI (rWIR < 2.3) is associated with shorter EFS even when adjusted for known clinical covariates and shows similar results to histological response evaluation. rWIR is a potential tool for future response-based individualized healthcare in osteosarcoma patients before surgical resection.

Publisher

MDPI AG

Reference29 articles.

1. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Hogendoorn;Ann. Oncol.,2014

2. Current approaches to management of bone sarcoma in adolescent and young adult patients;Ingley;Pediatr. Blood Cancer,2022

3. Osteosarcoma: A comprehensive review of management and treatment strategies;Jafari;Ann. Diagn. Pathol.,2020

4. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement;Huvos;Arch. Pathol. Lab. Med.,1977

5. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy;Rosen;Cancer,1982

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3